4.7 Article

Tackling burden in ART: an integrated approach for medical staff

Journal

HUMAN REPRODUCTION
Volume 27, Issue 4, Pages 941-950

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/humrep/der467

Keywords

assisted reproductive technology; in vitro fertilization; psychological; discontinuation; psychosocial interventions

Funding

  1. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA
  2. Merck Serono S.A.
  3. Merck Serono
  4. Schering Plough
  5. Merck
  6. EMD Serono
  7. Ferring
  8. Johnson Johnson
  9. Andromed
  10. Ardana
  11. Ferring, Genovum
  12. Glycotope
  13. MSD
  14. Organon
  15. Pantharei Bioscience
  16. Philips
  17. PregLem
  18. Schering
  19. Serono
  20. Wyeth

Ask authors/readers for more resources

Discontinuation is a problem in fertility clinics. Many couples discontinue assisted reproductive technologies (ART) without achieving a live birth for reasons other than poor prognosis or the cost of treatment. Discontinuation has been attributed to the burden of treatment. The causes of burden can be broadly classified according to whether they originate in the patient, clinic or treatment. Interventions to alleviate these burdens include provision of comprehensive educational material, screening to identify highly distressed patients, provision of tailored coping tools and improvements in the clinic environment and medical interventions. Practical interventions to reduce the different causes of burden in ART exist, but further development and evaluation of the efficacy of these interventions requires more precise definition of terms and theory. In this paper, we propose a general integrated approach to cover different perspectives in dealing with burden in ART clinics. We firstly describe the integrated approach and present common sources of burden. We then describe interventions that could help reduce the burden in ART. Our paper is aimed at fertility clinic staff because of their day-to-day involvement with patients. However, this discussion should also be relevant to companies that develop treatments and to psychosocial experts. Reducing the burden of treatment should lead to improved outcomes, namely better quality of life during treatment and lower discontinuation rates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available